Cubist Pharmaceuticals: Received Notification of Acceptance of Market Application for Naloxone Active Pharmaceutical Ingredient

Cubist Pharmaceuticals announced that it has recently received a "Notice of Acceptance" for the application for the market authorization of fluticasone raw material drug issued by the National Medical Products Administration. Fluticasone is a new type of salt corticosteroid receptor antagonist, and the formulation is used for adult patients with type 2 diabetes-related chronic kidney disease. As of the date of the announcement, among the 5 registered enterprises for this drug, 5 are in the "A" registration status, and the rest are in "I" status. The acceptance of this application means that the drug has entered the registration evaluation stage, with no significant impact on the company's recent performance. If the evaluation is successfully passed, it will enrich the company's raw material drug product pipeline. However, the registration approval result and time are uncertain, and investors should be aware of the risks.